Covered recipient · General Payments record
NEETU SHARMA
Allopathic & Osteopathic Physicians Internal Medicine Nephrology
General Payments · PY2022–2024
$292.53
- Reported across 15 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $225.48 | 11 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $60.04 | 3 |
| Novo Nordisk AS | $41.54 | 2 |
| Ardelyx, Inc. | $40.28 | 2 |
| Retrophin, Inc. | $25.54 | 1 |
| Azurity Pharmaceuticals, Inc. | $21.25 | 1 |
| Fresenius USA Marketing, Inc. | $18.66 | 1 |
| CALLIDITAS THERAPEUTICS US INC. | $18.17 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (11)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $21.61 | 01/31/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1116112339 | CMS |
| Amgen Inc. | $18.23 | 04/03/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1116112345 | CMS |
| Amgen Inc. | $20.20 | 06/06/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1117681496 | CMS |
| Ardelyx, Inc. | $19.08 | 01/18/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1146707404 | CMS |
| Ardelyx, Inc. | $21.20 | 02/07/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1146707406 | CMS |
| Azurity Pharmaceuticals, Inc. | $21.25 | 04/17/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1134012609 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $18.17 | 06/04/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1141516359 | CMS |
| Fresenius USA Marketing, Inc. | $18.66 | 07/11/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1154197070 | CMS |
| Novo Nordisk Inc | $18.53 | 06/12/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1097416992 | CMS |
| Novo Nordisk Inc | $23.01 | 06/26/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1097032858 | CMS |
| Travere Therapeutics, Inc. | $25.54 | 01/17/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1149954204 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2022, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.